Celltrion, the Korean biosimilars maker has budgeted $514 million (₩600 billion) over five years for a new plant in Wuhan, which it says will be China’s biggest biologics facility at a capacity of 120,000 liters. A groundbreaking ceremony is slated for April. Source: EndpointsNews 21/1/2020